Jan Terje Andersen head of hiv research program receiving 19 mill NOK

Jan Terje Andersen
Jan Terje Andersen

A consortium of University of Oslo, The International AIDS Vaccine Initiative (IAVI) and the Translational Health Science and Technology Institute (THSTI) has been granted 19.09 MNOK (about U.S. $2.2M) for a period of three years from the Research Council of Norway through the GLOBVAC (Global Health Vaccination and Research) program for the development of broadly neutralizing antibodies as HIV prevention products.

Teams on three continents will work to engineer and optimize antibodies to extend their half-life, an improvement designed to increase the duration of antibody activity and potentially lead to longer intervals between protective doses. The consortium is led by UiO.

The program is headed by Jan Terje Andersen, associate professor at the University of Oslo and leader of The Laboratory of Adaptive Immunity and Homeostasis at the Department of Immunology at Oslo University Hospital.


Jan Terje Andersen with researcher Stian Foss. Stian Foss is employed with the GLOBVAC project, and will bring the unique panel of antibodies to the USA, where he during the next year will study their properties at the prestigious Scripps Research Institute and the IAVI Neutralizing Antibody Center, led by Devin Sok. (photo: Simone Mester)

Press release (published on the IAVI home page):
University of Oslo, IAVI, and THSTI to Develop HIV Broadly Neutralizing Antibodies as a Prevention Product for Affordable Global Access

New articles (in Norwegian):

From Dagens medisin:
Får millioner til å forske på hiv

From national newspaper VG:
Millioner til forskning på hiv-medisin for kvinner

Home page of Jan Terje Andresen's research group:
The Laboratory of Adaptive Immunity and Homeostasis

The Laboratory of Adaptive Immunity and Homeostasis on social media:

Facebook page

LinkedIn page

On Twitter - @AndersenJT


Page visits: 7230